Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Phase 1/2 study of MP0533, a tetra-specific T cell engager (CD33 x CD123 x CD70 x CD3), in patients with relapsed/refractory AML or MDS/AML: Initial results from optimized treatment regimen including densified MP0533 dosing and adapted premedication

Pierre Bories, Mojca Jongen-Lavrencic, Laimonas Griškevičius, Thomas Pabst, David de Leeuw, Gerwin A. Huls, Nicolas Boissel, Arnaud Pigneux, Steffen Boettcher, Mariola Dymkowska, Christiane Andrieu, Elena Fernandez, Paul Baverel, Vaia Stavropoulou, Michael Sanderson, Vladimir Kirkin, Philippe Legenne, Marion Subklewe

Blood (2025) 146 (Supplement 1): 3419.

https://doi.org/10.1182/blood-2025-3419

Published: 2025

Journal Articles

Phase 3 Study of ivosidenib (IVO) and azacitidine (AZA) with or without venetoclax in adult patients with newly diagnosed IDH1-mutated AML or MDS/AML ineligible for intensive chemotherapy (EVOLVE-1)

Hartmut Döhner, Gerwin A. Huls, Paresh Vyas

Blood (2025) 146 (Supplement 1): 5192.

https://doi.org/10.1182/blood-2025-5192

Published: 2025

Journal Articles

Cholesterol biosynthesis-related genes reveal new opportunities for risk stratification and treatment in Acute Myeloid Leukemia

Maria Luiza Salustiano-Bandeira, Bruna Ormrod, Maria Fernanda Madrid Mendoza, César Alexander Ortiz Rojas, Amanda Aguiar, Diego Pereira-Martins, Juan Coelho-Silva, Jan Jacob Schuringa, Gerwin A. Huls, Antonio Lucena-Araujo, Eduardo Rego

Blood (2025) 146 (Supplement 1): 3505.

https://doi.org/10.1182/blood-2025-3505

Published: 2025

Journal Articles

BPI-2358 reprograms immunosuppressive macrophages and impairs leukemic progression in MN1-overexpressing AML In Vivo

Lucio Pinheiro, Isabel Weinhäuser, Diego Pereira-Martins, Katherine Hampton, Annalisa Altera, Dominic Fowler-Shorten, Matthew Markham, Alyssa Polski-Delve, Tabitha Bartlett, Charlotte Hellmich, Luise Araujo De Albuquerque Simoes, Cleide Lúcia Araujo, Rita De Cássia Cavaglieri Medeiros, Lynn Quek, Gerwin A. Huls, Jan Jacob Schuringa, Stuart Rushworth, Eduardo Rego

Blood (2025) 146 (Supplement 1): 5066.

https://doi.org/10.1182/blood-2025-5066

Published: 2025

Journal Articles

Higher helios⁺ treg levels pre- and post-CAR T infusion are associated with inferior outcomes in patients with LBCL

Hilde Van Der Galien, Nienke Smit, Marije Nijk, Marieke Tienstra, Thies Moolenaar, Janneke De Boer, Kylie Keijzer, Jaap Van Doesum, Anne Niezink, Gerwin A. Huls, Kees Meijer, Tom Van Meerten

Blood (2025) 146 (Supplement 1): 1779.

https://doi.org/10.1182/blood-2025-1779

Published: 2025

Journal Articles

Elevation of fetal hemoglobin is a biomarker for response to decitabine in AML: Results of the AML21 randomized phase III trial of the EORTC leukemia group, gimema and german MDS study group

Blood (2025) 146 (Supplement 1): 1709.

https://doi.org/10.1182/blood-2025-1709

Published: 2025

Journal Articles

Autologous stem cell transplantation versus consolidation chemotherapy as post-remission treatment in newly diagnosed favorable and intermediate risk patients with AML: A comparative analysis of HOVON-SAKK-Nordic trials

Dimitrios Kotsos, Carin Hazenberg, Thomas Pabst, Patrycja Gradowska, Markus Manz, Johan Maertens, Carlos Graux, Marie-Christiane Vekemans, Bjorn Gjertsen, Soren Lehmann, Catharina Van Elssen, Peter Valk, Edo Vellenga, Gert J. Ossenkoppele, Bob Lowenberg, Marc Raaijmakers, Gerwin A. Huls, Jurjen Versluis

Blood (2025) 146 (Supplement 1): 2517.

https://doi.org/10.1182/blood-2025-2517

Published: 2025

Journal Articles

10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: Long-term follow-up results of the randomized phase III trial AML21 of the EORTC leukemia group, GIMEMA and german MDS Study group

Blood (2025) 146 (Supplement 1): 1676.

https://doi.org/10.1182/blood-2025-1676

Published: 2025

Journal Articles

Bleximenib or placebo in combination with standard induction and consolidation therapy followed by maintenance for the treatment of patients with newly diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia eligible for intensive chemotherapy: A double-blind Phase 3 study (HOVON 181 AML / AMLSG 37-25)

Blood (2025) 146 (Supplement 1): 1654.

https://doi.org/10.1182/blood-2025-1654

Published: 2025

Journal Articles

MLL5-Driven Leukemic Transformation Is Linked to Chromatin Remodeling and Can be Targeted with ATRA in Combination with PARP1 Inhibition

Luise Araujo De Albuquerque Simoes, Isabel Weinhäuser, Diego A Pereira-Martins, Luciana Yamamoto Almeida, Vincent Van Den Boom, Fatemeh Mojallali, Dominique Sternadt, Prodromos Chatzikyriakou, Xuesen Zheng, César Alexander Ortiz Rojas, Ghulam Jeelani Mufti, Lucio Henrique Pinheiro, Lynn Quek, Gerwin A. Huls, Eduardo M. Rego, Jan Jacob Schuringa

Blood (2024) 144 (Supplement 1): 1539.

https://doi.org/10.1182/blood-2024-209817

Published: 2024

Journal Articles

Synergistic Effect of Tamoxifen and Ruxolitinib Combination in Reducing Disease Burden in Myeloproliferative Neoplasms

Diego A Pereira-Martins, Antonio Bruno Alves-Silva, Manuela Albuquerque De Melo, Natasha Peixoto Fonseca, Isabel Weinhäuser, Fabio Augusto Bueno Perez, Artur Bernardo Ribeiro Bellomi, Lorena Lobo Figueiredo-Pontes, João Agostinho Machado-Neto, Lynn Quek, Prodromos Chatzikyriakou, Gerwin A. Huls, Emanuele Ammatuna, Jan Jacob Schuringa, Fabiola Traina

Blood (2024) 144 (Supplement 1): 4518.

https://doi.org/10.1182/blood-2024-209823

Published: 2024

Journal Articles

Whole Body CD8 + T Cell PET Imaging in Patients with DLBCL before and during Anti-CD19 CAR T Cell Therapy

Jaap A. van Doesum, Kylie Keijzer, Janneke W. de Boer, Nienke A.M. Smit, Adrienne H. Brouwers, Marjolijn N. Lub-de Hooge, Frank R. Pierik, Gerwin A. Huls, Lisanne V. van Dijk, Lydia Visser, Arjan Diepstra, Walter Noordzij, Simon P. Williams, Alexander Ungewickell, Sjoerd G. Elias, Elisabeth G.E. de Vries, Anne G.H. Niezink, Tom van Meerten

Blood (2024) 144 (Supplement 1): 1037.

https://doi.org/10.1182/blood-2024-199474

Published: 2024

Journal Articles

CEBPA-Driven Expression of the Transcriptionally Inactive deltaTP73 Isoform Phenocopies TP53 mutated Poor Risk and Drug-Resistant Acute Myeloid Leukemia

Diego Pereira-Martins, César Alexander Ortiz Rojas, Isabel Weinhaeuser, Bart-Jan Wierenga, Vincent Van Den Boom, Fatemeh Mojallali, Dominique Sternadt, Thiago Mantello Bianco, Nisha van der Meer, Douglas RA Silveira, Lynn Quek, Emanuele Ammatuna, Antonio R Lucena-Araujo, Gerwin A. Huls, Eduardo Magalhães Rego, Jan Jacob Schuringa

Blood (2023) 142 (Supplement 1): 839.

https://doi.org/10.1182/blood-2023-186399

Published: 2023

Journal Articles

Outcome of Intensively Treated Elderly AML Patients Reported to the Harmony Alliance Compares Well to Outcome of Control Patients of the Prospective Randomized HOVON 103 Study in Elderly AML

Blood (2023) 142 (Supplement 1): 2854.

https://doi.org/10.1182/blood-2023-186277

Published: 2023

Journal Articles

Favorable Outcome of Abbreviated R-CHOP in Patients with Primary Testicular Lymphoma

Diana Al-Sarayfi, Mirian Brink, Mar Bellido, Wouter Plattel, Gerwin A. Huls, Marcel Nijland

Blood (2023) 142 (Supplement 1): 3115.

https://doi.org/10.1182/blood-2023-186261

Published: 2023

Journal Articles

Metformin-Induced Ferroptosis Is a Therapeutic Vulnerability in IDH2 -Mutant AML Linked to Metabolic Rewiring Towards Fatty Acid Oxidation

Dominique Sternadt, Diego Pereira-Martins, Douglas RA Silveira, Isabel Weinhaeuser, Ming Yang, Prodromos Chatzikyriakou, Pilar Casares Alaez, Emanuele Ammatuna, Lieve Oudejans, Gerwin A. Huls, Christian Frezza, Lynn Quek, Jan Jacob Schuringa

Blood (2023) 142 (Supplement 1): 1586.

https://doi.org/10.1182/blood-2023-188524

Published: 2023

Journal Articles

Reduction of Metabolic Active Tumor Volume Prior to CAR T-Cell Therapy Improves Survival Outcomes in Patients with Large B-Cell Lymphoma

Kylie Keijzer, Janneke W. de Boer, Jaap A. van Doesum, Walter Noordzij, Gerwin A. Huls, Lisanne V. van Dijk, Tom van Meerten, Anne G.H. Niezink

Blood (2023) 142 (Supplement 1): 4380.

https://doi.org/10.1182/blood-2023-173947

Published: 2023

Journal Articles

Cephalochromin-Induced Mitochondrial Damage Overcomes Venetoclax-Resistance in Acute Myeloid Leukemia Models

Mariane Cristina Do Nascimento, Diego A Pereira-Martins, Guilherme Augusto Sousa Alcântara, Keli Lima, Hugo Passos Vicari, Marcelo José Pena Ferreira, Leticia Veras Costa-Lotufo, Gerwin A. Huls, Jan Jacob Schuringa, João Agostinho Machado-Neto, Eduardo Magalhães Rego

Blood (2023) 142 (Supplement 1): 5751.

https://doi.org/10.1182/blood-2023-189814

Published: 2023

Journal Articles

First-in-Human Study of the CD123 NK Cell Engager SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia or High Risk-Myelodysplasia: Updated Safety, Efficacy, Pharmacokinetics and Pharmacodynamics

Blood (2023) 142 (Supplement 1): 3474.

https://doi.org/10.1182/blood-2023-173162

Published: 2023

Journal Articles

Impaired Metabolic Plasticity Under Stress Constitutes a Therapeutic Vulnerability in IDH1/2 -Mutant Acute Myeloid Leukemia

Dominique Sternadt, Diego Pereira-Martins, Douglas RA Silveira, Prodromos Chatzikyriakou, Maria del Pilar Casares Alaez, Isabel Weinhaeuser, Shanna M Hogeling, Emanuele Ammatuna, Gerwin A. Huls, Lynn Quek, Jan Jacob Schuringa

Blood (2022) 140 (Supplement 1): 8813–8814.

https://doi.org/10.1182/blood-2022-163282

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Phase 1/2 study of MP0533, a tetra-specific T cell engager (CD33 x CD123 x CD70 x CD3), in patients with relapsed/refractory AML or MDS/AML: Initial results from optimized treatment regimen including densified MP0533 dosing and adapted premedication

Phase 3 Study of ivosidenib (IVO) and azacitidine (AZA) with or without venetoclax in adult patients with newly diagnosed IDH1-mutated AML or MDS/AML ineligible for intensive chemotherapy (EVOLVE-1)

Cholesterol biosynthesis-related genes reveal new opportunities for risk stratification and treatment in Acute Myeloid Leukemia

BPI-2358 reprograms immunosuppressive macrophages and impairs leukemic progression in MN1-overexpressing AML In Vivo

Higher helios⁺ treg levels pre- and post-CAR T infusion are associated with inferior outcomes in patients with LBCL

Elevation of fetal hemoglobin is a biomarker for response to decitabine in AML: Results of the AML21 randomized phase III trial of the EORTC leukemia group, gimema and german MDS study group

Autologous stem cell transplantation versus consolidation chemotherapy as post-remission treatment in newly diagnosed favorable and intermediate risk patients with AML: A comparative analysis of HOVON-SAKK-Nordic trials

10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: Long-term follow-up results of the randomized phase III trial AML21 of the EORTC leukemia group, GIMEMA and german MDS Study group

MLL5-Driven Leukemic Transformation Is Linked to Chromatin Remodeling and Can be Targeted with ATRA in Combination with PARP1 Inhibition

Synergistic Effect of Tamoxifen and Ruxolitinib Combination in Reducing Disease Burden in Myeloproliferative Neoplasms

Whole Body CD8 + T Cell PET Imaging in Patients with DLBCL before and during Anti-CD19 CAR T Cell Therapy

CEBPA-Driven Expression of the Transcriptionally Inactive deltaTP73 Isoform Phenocopies TP53 mutated Poor Risk and Drug-Resistant Acute Myeloid Leukemia

Outcome of Intensively Treated Elderly AML Patients Reported to the Harmony Alliance Compares Well to Outcome of Control Patients of the Prospective Randomized HOVON 103 Study in Elderly AML

Favorable Outcome of Abbreviated R-CHOP in Patients with Primary Testicular Lymphoma

Metformin-Induced Ferroptosis Is a Therapeutic Vulnerability in IDH2 -Mutant AML Linked to Metabolic Rewiring Towards Fatty Acid Oxidation

Reduction of Metabolic Active Tumor Volume Prior to CAR T-Cell Therapy Improves Survival Outcomes in Patients with Large B-Cell Lymphoma

Cephalochromin-Induced Mitochondrial Damage Overcomes Venetoclax-Resistance in Acute Myeloid Leukemia Models

First-in-Human Study of the CD123 NK Cell Engager SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia or High Risk-Myelodysplasia: Updated Safety, Efficacy, Pharmacokinetics and Pharmacodynamics

Impaired Metabolic Plasticity Under Stress Constitutes a Therapeutic Vulnerability in IDH1/2 -Mutant Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only